Pharmacology of new and developing intravenous therapies for the management of seizures and epilepsy

References

• Palleria C, Coppola A, Citraro R, et al. Perspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis. Expert Opin Pharmacother. 2015;16:2355–2371.
   PubMed Web of Science ®Google Scholar
• Patel SI, Birnbaum AK, Cloyd JC, et al. Intravenous and intramuscular formulations of antiseizure drugs in the treatment of epilepsy. CNS Drugs. 2015;29:1009–1022.
   PubMed Web of Science ®Google Scholar
• Bialer M. Clinical pharmacology of parenteral use of antiepileptic drugs. Epilepsia. 2007;48(Suppl 8):46–48.
   PubMedGoogle Scholar
• Anderson GD, Saneto RP. Current oral and non-oral routes of antiepileptic drug delivery. Adv Drug Deliv Rev. 2012;64:911–918.
   PubMed Web of Science ®Google Scholar
• Riebesehl BU. The practice of medicinal chemistry. MA, USA: Elsevier; 2015. 699–722. Doi:10.1016/B978-0-12-417205-0.00029-8
   Google Scholar
• Misra UK, Kalita J, Patel R. Sodium valproate vs phenytoin in status epilepticus: a pilot study. Neurology. 2006;67(2):340–342.
   PubMed Web of Science ®Google Scholar
• Gilad R, Izkovitz N, Dabby R, et al. Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin. Acta Neurol Scand. 2008;118(5):296–300.
   PubMed Web of Science ®Google Scholar
• Agarwal P, Kumar N, Chandra R, et al. Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure. 2007;16(6):527–532.
   PubMed Web of Science ®Google Scholar
• Chen WB, Gao R, Su YY, et al. Valproate versus diazepam for generalized convulsive status epilepticus: a pilot study. Eur J Neurol. 2011;18(12):1391–1396.
   PubMed Web of Science ®Google Scholar
• Malamiri RA, Ghaempanah M, Khosroshahi N, et al. Efficacy and safety of intravenous sodium valproate versus phenobarbital in controlling convulsive status epilepticus and acute prolonged convulsive seizures in children: a randomised trial. Eur J Paediatr Neurol. 2012;16(5):536–541.
   PubMed Web of Science ®Google Scholar
• Mehta V, Singhi P. Singhi S Intravenous sodium valproate versus diazepam infusion for the control of refractory status epilepticus in children: a randomized controlled trial. J Child Neurol. 2007;22(10):1191–1197.
   PubMed Web of Science ®Google Scholar
• Su Y, Liu G, Tian F, et al. Phenobarbital versus valproate for generalized convulsive status epilepticus in adults: a prospective randomized controlled trial in China. CNS Drugs. 2016;30(12):1201–1207.
   PubMed Web of Science ®Google Scholar
• Chakravarthi S, Goyal MK, Modi M, et al. Levetiracetam versus phenytoin in management of status epilepticus. J Clin Neurosci. 2015;22(6):959–963.
   PubMed Web of Science ®Google Scholar
• Mundlamuri RC, Sinha S, Subbakrishna DK, et al. Management of generalised convulsive status epilepticus (SE): A prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam–pilot study. Epilepsy Res. 2015;114:52–58.
   PubMed Web of Science ®Google Scholar
• Gujjar AR, Nandhagopal R, Jacob PC, et al. Intravenous levetiracetam vs phenytoin for status epilepticus and cluster seizures: A prospective, randomized study. Seizure. 2017;49:8–12.
   PubMed Web of Science ®Google Scholar
• Misra UK, Dubey D, Kalita J. Comparison of lacosamide versus sodium valproate in status epilepticus: A pilot study. Epilepsy Behav. 2017;76:110–113.
   PubMed Web of Science ®Google Scholar
• Alvarez V, Januel JM, Burnand B, et al. Second-line status epilepticus treatment: comparison of phenytoin, valproate, and levetiracetam. Epilepsia. 2011;52(7):1292–1296.
   PubMed Web of Science ®Google Scholar
• Kellinghaus C, Berning S, Stögbauer F. Intravenous lacosamide or phenytoin for treatment of refractory status epilepticus. Acta Neurol Scand. 2014;129(5):294–299.
   PubMed Web of Science ®Google Scholar
• İşgüder R, Güzel O, Ceylan G, et al. A comparison of intravenous levetiracetam and valproate for the treatment of refractory status epilepticus in children. J Child Neurol. 2016;31(9):1120–1126.
   PubMed Web of Science ®Google Scholar
• Mumoli L, Palleria C, Gasparini S, et al. Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures. Drug Des Devel Ther. 2015;9:5719–5725.
   PubMed Web of Science ®Google Scholar
• Klein P, Diaz A, Gasalla T. A review of the pharmacology and clinical efficacy of brivaracetam. Clin Pharmacol. 2018;10:1–22.
   PubMed Web of Science ®Google Scholar
• Rogawski MA. Brivaracetam: a rational drug discovery success story. Br J Pharmacol. 2008;154:1555–1557.
   PubMed Web of Science ®Google Scholar
• Russo E, Citraro R, Mula M. The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy. Expert Opin Drug Discov. 2017;12:1169–1178.
   PubMed Web of Science ®Google Scholar
• Nicolas JM, Hannesta J, Holden D, et al. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia. 2016;57:201–209.
   PubMed Web of Science ®Google Scholar
• Stockis A, Hartstra J, Mollet M, et al. Bioavailability and bioequivalence comparison of brivaracetam 10, 50, 75, and 100 mg tablets and 100 mg intravenous bolus. Epilepsia. 2016;57:1288–1293.
   PubMed Web of Science ®Google Scholar
• Doty P, Rudd GD, Stoehr T, et al. Lacosamide. Neurotherapeutics. 2007;4:145–148.
   PubMed Web of Science ®Google Scholar
• Ruffolo G, Di Bonaventura C, Cifelli P, et al. A novel action of lacosamide on GABAA currents sets the ground for a synergic interaction with levetiracetam in treatment of epilepsy. Neurobiol Dis. 2018;115:59–68.
   PubMed Web of Science ®Google Scholar
• Cawello W. Clinical pharmacokinetic and pharmacodynamic profile of lacosamide. Clin Pharmacokinet. 2015;54:901–914.
   PubMed Web of Science ®Google Scholar
• Bauer S, Willems LM, Paule E, et al. The efficacy of lacosamide as monotherapy and adjunctive therapy in focal epilepsy and its use in status epilepticus: clinical trial evidence and experience. Ther Adv Neurol Disord. 2017;10:103–126.
   PubMed Web of Science ®Google Scholar
• Lang N, Lange M, Schmitt FC, et al. Intravenous lacosamide in clinical practice-Results from an independent registry. Seizure. 2016;39:5–9.
   PubMed Web of Science ®Google Scholar
• Li W, Stefan H, Matzen J, et al. Rapid loading of intravenous lacosamide: efficacy and practicability during presurgical video-EEG monitoring. Epilepsia. 2013;54:75–80.
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA. Levetiracetam: a review of its use in epilepsy. Drugs. 2011;71:489–514.
   PubMed Web of Science ®Google Scholar
• Palma E, Ragozzino D, Di Angeloantonio S, et al. The antiepileptic drug levetiracetam stabilizes the human epileptic GABAA receptors upon repetitive activation. Epilepsia. 2007;48:1842–1849.
   PubMed Web of Science ®Google Scholar
• Patsalos PN. Clinical Pharmacokinetics of Levetiracetam. Clin Pharmacokinet. 2004;43:707–724.
   PubMed Web of Science ®Google Scholar
• Sisodiya SM, Sander JWAS, Patsalos PN. Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. Epilepsy Res. 2002;48:217–219.
   PubMed Web of Science ®Google Scholar
• Glauser TA, Pellock JM, Bebin EM, et al. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia. 2002;43:518–524.
   PubMed Web of Science ®Google Scholar
• Ramael S, De Smedt F, Toublanc N, et al. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Clin Ther. 2006;28:734–744.
   PubMed Web of Science ®Google Scholar
• Ramael S, Daoust A, Otoul C, et al. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia. 2006;47(7):1128–1135.
   PubMed Web of Science ®Google Scholar
• Tomson T, Battino D, Perucca E. Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug. Lancet Neurol. 2016;15:210–218.
   PubMed Web of Science ®Google Scholar
• Johannessen CU, Johannessen SI. Valproate: past, present, and future. CNS Drug Rev. 2003;9:199–216.
   PubMedGoogle Scholar
• Göttlicher M. Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. Ann Hematol. 2004;83(Suppl 1):S91–2.
   PubMedGoogle Scholar
• Methaneethorn J. A systematic review of population pharmacokinetics of valproic acid. Br J Clin Pharmacol. 2018;84:816–834.
   PubMed Web of Science ®Google Scholar
• Verrotti A, Mencaroni E, Cofini M, et al. Valproic acid metabolism and its consequences on sexual functions. Curr Drug Metab. 2016;17:573–581.
   PubMed Web of Science ®Google Scholar
• Gerstner T, Bell N, König S. Oral valproic acid for epilepsy–long-term experience in therapy and side effects. Expert Opin Pharmacother. 2008;9(2):285–292.
   PubMed Web of Science ®Google Scholar
• Perucca E, Gatti G, Frigo GM, et al. Pharmacokinetics of valproic acid after oral and intravenous administration. Br J Clin Pharmacol. 1978;5:313–318.
   Web of Science ®Google Scholar
• Georgoff PE, Nikolian VC, Bonham T, et al. Safety and tolerability of intravenous valproic acid in healthy subjects: a Phase I dose-escalation trial. Clin Pharmacokinet. 2018;57:209–219.
   PubMed Web of Science ®Google Scholar
• Chen ZW, Bracamontes JR, Budelier MM, et al. A multiple functional neurosteroid binding sites on GABA A receptors. bioRxiv. 2018. DOI:10.1101/357574.
   Google Scholar
• Rogawski MA, Loya CM, Reddy K, et al. Neuroactive steroids for the treatment of status epilepticus. Epilepsia. 2013;54(Suppl 6):93–98.
   PubMed Web of Science ®Google Scholar
• Rosenthal ES, Claassen J, Wainwright MS, et al. Brexanolone as adjunctive therapy in super-refractory status epilepticus. Ann Neurol. 2017;82:342–352.
   PubMed Web of Science ®Google Scholar
• Meletti S, Lucchi C, Monti G, et al. Decreased allopregnanolone levels in cerebrospinal fluid obtained during status epilepticus. Epilepsia. 2017;58:e16–e20.
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levi LH, et al. Progress report on new antiepileptic drugs: A summary of the thirteenth eilat conference on new antiepileptic drugs and devices (EILAT XIII). Epilepsia. 2017;58:181–221.
   PubMed Web of Science ®Google Scholar
• De Caro C, Leo A, Citraro R, et al. The potential role of cannabinoids in epilepsy treatment. Expert Rev Neurother. 2017;17:1069–1079.
   PubMed Web of Science ®Google Scholar
• Leo A, Russo E, Elia M. Cannabidiol and epilepsy: rationale and therapeutic potential. Pharmacol Res. 2016;107:85–92.
   PubMed Web of Science ®Google Scholar
• Morano A, Cifelli P, Nencini P, et al. Cannabis in epilepsy: from clinical practice to basic research focusing on the possible role of cannabidivarin. Epilepsia Open. 2016;1:145–151.
   PubMedGoogle Scholar
• Stahl SM. Stahl’s essential psychopharmacology : neuroscientific basis and practical application. 4th ed. Cambridge, UK: Cambridge University Press; 2013.
   Google Scholar
• Klein P, Tolbert D. Intravenous carbamazepine: a new formulation of a familiar drug. Expert Rev Neurother. 2017;7:851–860.
   Google Scholar
• Franco V, Iudice A, Grillo E, et al. Perspective on the use of perampanel and intravenous carbamazepine for generalized seizures. Expert Opin Pharmacother. 2014;15:637–644.
   PubMed Web of Science ®Google Scholar
• Conway JM, White JR, Birnbaum AK, et al. Safety of an IV formulation of carbamazepine. Epilepsy Res. 2009;4:242–244.
   Google Scholar
• Lee D, Kalu U, Halford JJ, et al. Intravenous carbamazepine as short-term replacement therapy for oral carbamazepine in adults with epilepsy: pooled tolerability results from two open-label trials. Epilepsia. 2015;56:906–914.
   PubMed Web of Science ®Google Scholar
• Marino SE, Birnbaum AK, Leppin IE, et al. Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex. Clin Pharmacol Ther. 2012;91:483–488.
   PubMed Web of Science ®Google Scholar
• Brigo F, Leo A, Russo E, et al. Intravenous carbamazepine for the treatment of epilepsy. Expert Opin Pharmacother. 2018;9:743–747.
   Google Scholar
• Vickery PB, Tillery EE, DeFalco AP. Intravenous carbamazepine for adults with seizures. Ann Pharmacother. 2018;52:285–289.
   PubMed Web of Science ®Google Scholar
• Yasam VR, Jakki SL, Senthil V, et al. A pharmacological overview of lamotrigine for the treatment of epilepsy. Expert Rev Clin Pharmacol. 2016;9:1533–1546.
   PubMed Web of Science ®Google Scholar
• Stefani A, Spadoni F, Siniscalchi A, et al. Lamotrigine inhibits Ca2+ currents in cortical neurons: functional implications. Eur J Pharmacol. 1996;307:113–6hu.
   PubMed Web of Science ®Google Scholar
• Zona C, Tancredi V, Longone P, et al. Neocortical potassium currents are enhanced by the antiepileptic drug lamotrigine. Epilepsia. 2002;43:685–690.
   PubMed Web of Science ®Google Scholar
• Biton V. Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy. Expert Opin Drug Metab Toxicol. 2006;2:1009–1018.
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Yuen AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 study group. Epilepsy Res. 1997;26:423–432.
   PubMed Web of Science ®Google Scholar
• Weston J, Bromley R, Jackson CF, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev. 2016;11:CD010224.
   PubMedGoogle Scholar
• Conway JM, Birnbaum AK, Leppik IE, et al. Safety of an intravenous formulation of lamotrigine. Seizure. 2014;23:390–392.
   PubMed Web of Science ®Google Scholar
• Russo E, Constanti A, Ferreri G, et al. Nifedipine affects the anticonvulsant activity of topiramate in various animal models of epilepsy. Neuropharmacology. 2004;46:865–878.
   PubMed Web of Science ®Google Scholar
• Russo E, Constanti A. Topiramate hyperpolarizes and modulates the slow poststimulus AHP of rat olfactory cortical neurones in vitro. Br J Pharmacol. 2004;141:285–301.
   PubMed Web of Science ®Google Scholar
• Latini G, Verrotti A, Manco R, et al. Topiramate: its pharmacological properties and therapeutic efficacy in epilepsy. Topiramate: its pharmacological properties and therapeutic efficacy in epilepsy. Mini Rev Med Chem. 2008;8(1):10–23.
   PubMed Web of Science ®Google Scholar
• Clark AM, Kriel RL, Leppik IE, et al. Intravenous topiramate: comparison of pharmacokinetics and safety with the oral formulation in healthy volunteers. Epilepsia. 2013;54:1099–1105.
   PubMed Web of Science ®Google Scholar
• Clark AM, Kriel RL, Leppik IE, et al. Intravenous topiramate: safety and pharmacokinetics following a single dose in patients with epilepsy or migraines taking oral topiramate. Epilepsia. 2013;54:1106–1111.
   PubMed Web of Science ®Google Scholar
• Silverstein FS, Ferriero DM. Off-Label use of antiepileptic drugs for the treatment of neonatal seizures. Pediatr Neurol. 2008;39:77–79.
   PubMed Web of Science ®Google Scholar
• Yozawitz E, Stacey A, Pressler RM. Pharmacotherapy for seizures in neonates with hypoxic ischemic encephalopathy. Paediatr Drugs. 2017;19:553–567.
   PubMed Web of Science ®Google Scholar
• Lopez-Samblas AM, Adams JA, Goldberg RN, et al. The pharmacokinetics of bumetanide in the newborn infant. Biol Neonate. 1997;72:265–272.
   PubMedGoogle Scholar
• Payne JA, Rivera C, Voipio J, et al. Cation–chloride co-transporters in neuronal communication, development and trauma. Trends Neurosci. 2003;26:199–206.
   PubMed Web of Science ®Google Scholar
• Dzhala VI, Thalos DM, Sdrulla DA, et al. NKCC1 transporter facilitates seizures in the developing brain. Nat Med. 2005;11:1205–1213.
   PubMed Web of Science ®Google Scholar
• Kahle KT, Barnett SM, Sassower KC, et al. Decreased seizure activity in a human neonate treated with bumetanide, an inhibitor of the Na(+)-K(+)-2Cl(-) cotransporter NKCC1. J Child Neurol. 2009;24:572–576.
   PubMed Web of Science ®Google Scholar
• Pressler RM, Boylan GB, Marlow N, et al. Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial. Lancet Neurol. 2015;14:469–475.
   PubMed Web of Science ®Google Scholar
• Eftekhari S, Mehvari Habibabadi J, Najafi Ziarani M, et al. Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy. Epilepsia. 2013;54:e9–12.
   PubMed Web of Science ®Google Scholar
• Sinner B, Graf BM. Ketamine. Handb Exp Pharmacol. 2008;313–33:2008.
   Google Scholar
• Fang Y, Wang X. Ketamine for the treatment of refractory status epilepticus. Seizure. 2015;30:14–20.
   PubMed Web of Science ®Google Scholar
• Rosati A, De Masi S, Guerrini R. Ketamine for refractory status epilepticus: a systematic review. CNS Drugs. 2018 Sep 19. [Epub ahead of print]. DOI:10.1007/s40263-018-0569-6
   PubMed Web of Science ®Google Scholar
• G J I, Visnjevac O, Pourafkari L, et al. Ketamine: an update on cellular and subcellular mechanisms with implications for clinical practice. Pain Physician. 2017;20:E285–E301.
   PubMed Web of Science ®Google Scholar
• Craven R. Ketamine. Anaesthesia. 2007;62(Suppl 1):48–53.
   PubMedGoogle Scholar
• Ahlmann M, Hempel G. The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy. Cancer Chemoth Pharmacol. 2016;78:661–671.
   PubMed Web of Science ®Google Scholar
• de Jonge ME, Huitema ADR, Rodenhuis S, et al. Clinical Pharmacokinetics of cyclophosphamide. Clin Pharmacokinet. 2005;44:1135–1164.
   PubMed Web of Science ®Google Scholar
• Lünemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology–mode of action and clinical efficacy. Nat Rev Neurol. 2015;11:80–89.
   PubMed Web of Science ®Google Scholar
• Koleba T, Ensom MHH. Pharmacokinetics of intravenous immunoglobulin: a systematic review. Pharmacotherapy. 2006;26:813–827.
   PubMed Web of Science ®Google Scholar
• Kosmidis ML, Dalakas MC. Practical considerations on the use of rituximab in autoimmune neurological disorders. Ther Adv Neurol Disord. 2010;3:93–105.
   PubMedGoogle Scholar
• Bhatia S, Schmitt SE. Treating immune-related epilepsy. Curr Neurol Neurosci Rep. 2018;18:10.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol. 2008;4:557–567.
   PubMedGoogle Scholar
• Golay J, Semenzato G, Rambaldi A, et al. Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs. 2013;5:826–837.
   PubMed Web of Science ®Google Scholar
• Bien CG, Granata T, Antozzi C, et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: A European consensus statement. Brain. 2005;128:454–471.
   PubMed Web of Science ®Google Scholar
• Granata T, Andermann F. Rasmussen encephalitis. Handb Clin Neurol. 2013;111:511–519.
   PubMedGoogle Scholar
• Bien CG, Tiemeier H, Sassen R, et al. Rasmussen encephalitis: incidence and course under randomized therapy with tacrolimus or intravenous immunoglobulins. Epilepsia. 2013;54:543–550.
   PubMed Web of Science ®Google Scholar
• Thilo B, Stingele R, Knudsen K, et al. A case of Rasmussen encephalitis treated with rituximab. Nat Rev Neurol. 2009;5:458–462.
   PubMed Web of Science ®Google Scholar
• Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15:391–404.
   PubMed Web of Science ®Google Scholar
• Shin YW, Lee ST, Park KI, et al. Treatment strategies for autoimmune encephalitis. Ther Adv Neurol Disord. 2018;11:1–19.
   Web of Science ®Google Scholar
• Gastaldi M, Thouin A, Vincent A. Antibody-mediated autoimmune encephalopathies and immunotherapies. Neurotherapeutics. 2016;13:147–162.
   PubMed Web of Science ®Google Scholar
• Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2016;12:157–165.
   Google Scholar
• Lee WJ, Lee ST, Byun JI, et al. Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort. Neurology. 2016;86:1683–1691.
   PubMed Web of Science ®Google Scholar
• Shorvon SD, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain. 2011;134:2802–2818.
   PubMed Web of Science ®Google Scholar
• Khawaja AM, Vines BL, Miller DW, et al. Refractory status epilepticus and glutamic acid decarboxylase antibodies in adults: presentation, treatment and outcomes. Epileptic Disord. 2015;18:34–43.
   Web of Science ®Google Scholar
• Caputo D, Iorio R, Vigevano F, et al. Febrile infection-related epilepsy syndrome (FIRES) with super-refractory status epilepticus revealing autoimmune encephalitis due to GABAAR antibodies. Eur J Paediatr Neurol. 2018;22:182–185.
   PubMed Web of Science ®Google Scholar
• Gaspard N, Hirsch LJ, Sculier C, et al. New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): state of the art and perspectives. Epilepsia. 2018;59(4):745–752.
   PubMed Web of Science ®Google Scholar
• Bello-Espinosa LE, Rajapakse T, Rho JM, et al. Efficacy of intravenous immunoglobulin in a cohort of children with drug-resistant epilepsy. Pediatr Neurol. 2015;52:509–516.
   PubMed Web of Science ®Google Scholar
• Mikati MA, Saab R, Fayad MN, et al. Efficacy of intravenous immunoglobulin in Landau-Kleffner syndrome. Pediatr Neurol. 2002;26:298–300.
   PubMed Web of Science ®Google Scholar
• Auvin S, Cilio MR, Vezzani A. Current understanding and neurobiology of epileptic encephalopathies. Neurobiol Dis. 2016;92:72–89.
   PubMed Web of Science ®Google Scholar
• Elovaara I, Apostolski S, van Doorn P, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol. 2008;15:893–908.
   PubMed Web of Science ®Google Scholar
• Geng J, Dong J, Li Y, et al. Intravenous immunoglobulins for epilepsy. Cochrane Database Syst Rev. 2017;7:CD008557.
   PubMedGoogle Scholar
• van Rijckevorsel-Harmant K, Delire M, Schmitz-Moorman W, et al. Treatment of refractory epilepsy with intravenous immunoglobulins. Results of the first double-blind/dose finding clinical study. Int J Clin Lab Res. 1994;24:162–166.
   PubMedGoogle Scholar
• Trinka E, Höfler J, Zerbs A, et al. Efficacy and safety of intravenous valproate for status epilepticus: a systematic review. CNS Drugs. 2014;28:623–639.
   PubMed Web of Science ®Google Scholar
• Yasiry Z, Shorvon SD. The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies. Seizure. 2014;23:167–174.
   PubMed Web of Science ®Google Scholar
• Cock HR & ESETT Group. Established Status Epilepticus Treatment Trial (ESETT). Epilepsia. 2011;52:50–52.
   Google Scholar
• Lapenta L, Morano A. Casciato, et al. Clinical experience with intravenous valproate as first-line treatment of status epilepticus and seizure clusters in selected populations. Int J Neurosci. 2014;124:30–36.
   PubMed Web of Science ®Google Scholar
• Fattouch J, Di Bonaventura C, Casciato S, et al. Intravenous Levetiracetam as first-line treatment of status epilepticus in the elderly. Acta Neurol Scand. 2010;121:418–421.
   PubMed Web of Science ®Google Scholar
• Misra UK, Kalita J, Maurya PK. Levetiracetam versus lorazepam in status epilepticus: a randomized, open labeled pilot study. J Neurol. 2012;259(4):645–648.
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Zöllner JP, Willems LM, et al. Lacosamide in status epilepticus: systematic review of current evidence. Epilepsia. 2017 Jun;58(6):933–950.
   PubMed Web of Science ®Google Scholar
• Husain AM, Lee JW, Kolls BJ, et al. Randomized trial of lacosamide vs fosphenytoin for nonconvulsive seizures. Ann Neurol. 2018. DOI:10.1002/ana.25249.
   PubMed Web of Science ®Google Scholar
• Trinka E, Höfler J, Leitinger M, et al. Pharmacologic treatment of status epilepticus. Expert Opin Pharmacother. 2016;17:513–534.
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Steinig I, Willems LM, et al. Treatment of refractory and super-refractory status epilepticus with brivaracetam: A cohort study from two German university hospitals. Epilepsy Behav. 2017;70:177–181.
   PubMed Web of Science ®Google Scholar
• Broomall E, Natale JE, Grimason M, et al. Pediatric super-refractory status epilepticus treated with allopregnanolone. Ann Neurol. 2014;76:911–915.
   PubMed Web of Science ®Google Scholar
• Vaitkevicius H, Husain AM, Rosenthal ES, et al. First-in-man allopregnanolone use in super-refractory status epilepticus. Ann Clin Transl Neurol. 2017;4:411–414.
   PubMed Web of Science ®Google Scholar
• Rossetti AO. Place of neurosteroids in the treatment of status epilepticus. Epilepsia. 2018;29. [Epub ahead of print]. DOI:10.1111/epi.14481
   Google Scholar
• Wichards WSW, Schobben AFAM, Leijten FSS. Perioperative substitution of anti-epileptic drugs. J Neurol. 2013;260:2865–2875.
   PubMed Web of Science ®Google Scholar
• Khan AA, Banerjee A. The role of prophylactic anticonvulsants in moderate to severe head injury. Int J Emerg Med. 2010;3:187–191.
   PubMedGoogle Scholar
• Thompson K, Pohlmann-Eden B, Campbell LA, et al. Pharmacological treatments for preventing epilepsy following traumatic head injury. Cochrane Database Syst Rev. 2015;(8):CD009900.
   PubMed Web of Science ®Google Scholar
• Carney N, Totten AM, O’Reilly C, et al. Guidelines for the management of severe traumatic brain injury, fourth edition. Neurosurgery. 2017;80(1):6–15.
   PubMed Web of Science ®Google Scholar
• Kruer RM, Harris LH, Goodwin H, et al. Changing trends in the use of seizure prophylaxis after traumatic brain injury: a shift from phenytoin to levetiracetam. J Crit Care. 2013;28(5):883.e9–13.
   PubMed Web of Science ®Google Scholar
• Szaflarski JP, Sangha KS, Lindsell CJ, et al. A Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care. 2010;12:165–172.
   PubMed Web of Science ®Google Scholar
• Inaba K, Menaker J, Branco BC, et al. A prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizure prophylaxis. J Trauma Acute Care Surg. 2013;74(3):766–771.
   PubMed Web of Science ®Google Scholar
• Jones KE, Puccio AM, Harshman KJ, et al. Levetiracetam versus phenytoin for seizure prophylaxis in severe traumatic brain injury. Neurosurg Focus. 2008;25(4):E3.
   PubMed Web of Science ®Google Scholar
• Temkin NR, Dikmen SS, Anderson GD, et al. Valproate therapy for prevention of posttraumatic seizures: a randomized trial. J Neurosurg. 1999;91:593–600.
   PubMed Web of Science ®Google Scholar
• Ma C, Xue Y, Li M, et al. Sodium valproate for prevention of early posttraumatic seizures. Chinese J Traumatol. 2010;13(5):293–296.
   PubMedGoogle Scholar
• Weston J, Greenhalgh J, Marson AG. Antiepileptic drugs as prophylaxis for post-craniotomy seizures. Cochrane Database Syst Rev. 2015;CD007286.
   PubMed Web of Science ®Google Scholar
• Dewan MC, Thompson RC, Kalkanis SN, et al. Prophylactic antiepileptic drug administration following brain tumor resection: results of a recent AANS/CNS Section on Tumors survey. J Neurosurg. 2017;126:1772–1778.
   PubMed Web of Science ®Google Scholar
• Siomin V, Angelov L, Li L, et al. Results of a survey of neurosurgical practice patterns regarding the prophylactic use of anti-epilepsy drugs in patients with brain tumors. J Neurooncol. 2005;74:211–215.
   PubMed Web of Science ®Google Scholar
• Fuller KL, Wang YY, Cook MJ, et al. Tolerability, safety, and side effects of levetiracetam versus phenytoin in intravenous and total prophylactic regimen among craniotomy patients: a prospective randomized study. Epilepsia. 2013;54:45–57.
   PubMed Web of Science ®Google Scholar
• Beenen LF, Lindeboom J, Kasteleijn-Nolst Trenité DG, et al. Comparative double blind clinical trial of phenytoin and sodium valproate as anticonvulsant prophylaxis after craniotomy: efficacy, tolerability, and cognitive effects. J Neurol Neurosurg Psychiatry. 1999;67:474–480.
   PubMed Web of Science ®Google Scholar